Drug development,
Ecosystem,
Heat Biologics,
Private Securities Litigation Reform Act,
Immune system,
Twitter,
Maintenance,
GLOBE,
Company,
NYSE,
Annual report,
Safety,
Time,
Drug discovery,
Industry,
Form 10-K,
Elusys Therapeutics,
Marketing,
Sale,
SEC,
Life,
Terminology,
CEO,
Growth,
Therapy,
Fine chemical,
Pharmaceutical industry In connection with the name change, the Companys ticker will change to NHWK, effective today, May 3, 2022.
Key Points:
- In connection with the name change, the Companys ticker will change to NHWK, effective today, May 3, 2022.
- Jeff Wolf, CEO of Nighthawk, commented, The NightHawk brand better reflects our evolution towards a fully integrated ecosystem, designed to efficiently move drugs from discovery through commercialization.
- As a result, we have organized the Company around five key subsidiaries: Skunkworx Bio , Heat Biologics , Pelican Therapeutics , Elusys Therapeutics and Scorpion Biological Services .
- NightHawk Biosciences is a fully integrated biopharmaceutical company focused on the development of new drugs from discovery through commercialization.
Retrieved on:
Wednesday, April 27, 2022
ANTHIM will be delivered to Canadas National Emergency Strategic Stockpile under a procurement contract totaling CAD $7.9 millioni.
Key Points:
- ANTHIM will be delivered to Canadas National Emergency Strategic Stockpile under a procurement contract totaling CAD $7.9 millioni.
- The goal of this program is to establish a Canadian supply of Anthim for use as a medical countermeasure against natural and man-made anthrax biothreats.
- We are focused on expanding sales of ANTHIM, abroad and this first international contract is an important validation of our strategy.
- Elusys Therapeutics is focused on the development of antibody therapeutics for the treatment of infectious disease.
Retrieved on:
Wednesday, April 20, 2022
DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed “NightHawk Biosciences”), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it has completed the acquisition of Elusys Therapeutics, Inc. a commercial-stage biodefense company and developer of ANTHIM® (obiltoxaximab), a treatment for inhalation anthrax. ANTHIM® is approved for use in the U.S. and Canada, and under the brand name Obiltoxaximab SFL in Europe and the United Kingdom.
Key Points:
- No stock or warrants were issued in connection with the acquisition, and Elusys had no outstanding term debt.
- The strategic acquisition of Elusys significantly expands the Companys role in the biodefense space, complementing NightHawks RapidVax platform, which is designed to target emerging biological threats.
- Elusys has an established a successful track record collaborating with U.S. government agencies including BARDA, NIH, SNS and DOD.
- Heat Biologics (to become NightHawk Biosciences) is a fully-integrated biopharmaceutical company focused on the development of new drugs from discovery through biomanufacturing.
Drug development,
Annual report,
Thought,
Marketing,
Adult,
Nighthawk,
Twitter,
Research,
Bacillus anthracis,
Life,
Private Securities Litigation Reform Act,
Hypersensitivity,
Drug discovery,
GLOBE,
Anaphylaxis,
Terminology,
Patient,
Sale,
Infection,
American Association for Cancer Research,
Form 10-K,
Kansas State University,
Scorpion,
Efficiency,
Growth,
Heat Biologics,
Company,
Immune system,
Anthrax,
Ecosystem,
Discovery,
Nasdaq,
Maintenance,
SEC,
Joint Chiefs of Staff,
NYSE,
Investment,
Safety,
American Association,
Acquisition,
Chief of staff,
Risk,
AACR,
Obiltoxaximab,
Therapy,
Time,
Pharmaceutical industry,
Pelican,
Elusys Therapeutics,
Heat In connection with the name change, the Companys ticker will change to NHWK, effective May 3, 2022.
Key Points:
- In connection with the name change, the Companys ticker will change to NHWK, effective May 3, 2022.
- The Company believes this fully-integrated ecosystem enables a more rapid delivery of medical innovations with increased quality and efficiency.
- Scorpion is expected to host the grand opening of its San Antonio facility following completion of construction in Q3, 2022.
- About Heat Biologics / NightHawk Biosciences, Inc.
Heat Biologics (to become NightHawk Biosciences) is a fully-integrated biopharmaceutical company focused on the development of new drugs from discovery through manufacturing.
DURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Heat) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, reminds investors that it will host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments.
Key Points:
- DURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Heat) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, reminds investors that it will host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments.
- The event will be broadcast at: https://vimeo.com/event/2027558/fc6de52c31
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies and vaccines to modulate the immune system.
- Heats gp96 platform is designed to activate immune responses against cancer or infectious diseases.
- The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in a Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
BRI,
Drug development,
Annual report,
Marketing,
Cell biology,
National Bio and Agro-Defense Facility,
Research,
CDMO,
Foot,
Private Securities Litigation Reform Act,
GLOBE,
Sale,
Terminology,
Patient,
Engineering,
Form 10-K,
Kansas State University,
Growth,
Infection,
Scorpion,
Virology,
Heat Biologics,
RTG,
Company,
Immune system,
CT,
Vaccine,
Nasdaq,
Maintenance,
SEC,
NBAF,
NYSE,
Investment,
Safety,
Partnership,
Acquisition,
Bioreactor,
Precision medicine,
Secretary of State of Kansas,
Time,
Cancer,
Contract,
Pharmaceutical industry,
Elusys Therapeutics,
Heat DURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Heat) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, today announced a planned development partnership of its Scorpion Biological Services subsidiary with a private developer, the State of Kansas and local and university affiliates, to support the development of a new biodefense-focused large molecule and biologics biomanufacturing facility in Manhattan, Kansas. Manhattan is the home of Kansas State University (K-State), its Biosecurity Research Institute (BRI), and the National Bio and Agro-Defense Facility (NBAF).
Key Points:
- Manhattan is the home of Kansas State University (K-State), its Biosecurity Research Institute (BRI), and the National Bio and Agro-Defense Facility (NBAF).
- The facility is expected to have a billion-dollar economic impact within the State of Kansas.
- David Halverson, President of Heats Scorpion subsidiary, noted, We are very excited to break ground on this new facility.
- Jeff Wolf, Chief Executive Officer of Heat, commented, Today, we are very proud to unveil our plans for our newest biomanufacturing facility in Manhattan, Kansas.
DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Heat) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, today announced it plans to host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments.
Key Points:
- DURHAM, N.C., April 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Heat) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, today announced it plans to host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments.
- The event will be broadcast at: https://vimeo.com/event/2027558/fc6de52c31
Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies and vaccines to modulate the immune system.
- Heats gp96 platform is designed to activate immune responses against cancer or infectious diseases.
- The Company has multiple product candidates in development leveraging the gp96 platform, including HS-110, which has completed enrollment in a Phase 2 trial, various infectious disease/biological threat programs in preclinical development and a pipeline of proprietary immunomodulatory antibodies and cell-based therapies, including PTX-35 and HS-130 in Phase 1 clinical trials.
Adoption,
Private Securities Litigation Reform Act,
Company,
Form 10-K,
Sale,
Investment,
Marketing,
Growth,
NYSE,
Annual report,
Nasdaq,
Vaccine,
Research,
SEC,
Cancer,
Scorpion,
Immune system,
Safety,
CDMO,
Heat Biologics,
Time,
GLOBE,
Efficiency,
Terminology,
FDA,
Maintenance,
Patient,
Infection,
Pharmaceutical industry,
Heat DURHAM, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Heat) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, today unveiled enhanced allogeneic cell therapy manufacturing capabilities through its Scorpion Biological Services subsidiary.
Key Points:
- DURHAM, N.C., March 25, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Heat) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, today unveiled enhanced allogeneic cell therapy manufacturing capabilities through its Scorpion Biological Services subsidiary.
- Jeff Wolf, Chief Executive Officer of Heat, commented, We are excited to rollout our new 3-D allogeneic cell manufacturing capabilities to replace our current 2-D HS-110 manufacturing.
- One of the greatest challenges to broad adoption of cell therapies has been the time and cost of production.
- Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies and vaccines to modulate the immune system.
Retrieved on:
Wednesday, March 23, 2022
Company,
Private Securities Litigation Reform Act,
Pandemic,
Form 10-K,
Mass,
Heat Biologics,
Sale,
Federal Emergency Management Agency,
Biological defense,
Investment,
Marketing,
GSA,
Public health,
Growth,
NYSE,
Patient,
Annual report,
Nasdaq,
General Services Administration,
Vaccine,
Research,
SEC,
Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs,
Associate,
Cancer,
Weapon,
Assistant,
SNS,
Strategic National Stockpile,
Immune system,
Safety,
Office of the Assistant Secretary for Preparedness and Response,
FEMA,
Time,
COVID-19,
GLOBE,
Defense,
United States Department of Health and Human Services,
Department,
COVID,
George Mason University,
Maintenance,
Terminology,
Chemical substance,
ASPR,
Infection,
Pharmaceutical industry,
Elusys Therapeutics,
Heat In addition, his prior service includes senior management roles with increasing responsibility with the Federal Emergency Management Agency (FEMA) and the General Services Administration (GSA).
Key Points:
- In addition, his prior service includes senior management roles with increasing responsibility with the Federal Emergency Management Agency (FEMA) and the General Services Administration (GSA).
- Mr. Burel recently retired after nearly 38 years of federal service in January of 2020.
- The COVID pandemic has only reinforced the urgent need for a rapid, safe, and effective response to potential biological threats.
- Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies and vaccines to modulate the immune system.
Large-cell lung carcinoma,
Maintenance,
Contract,
D&O,
American Association for Cancer Research,
Regulatory T cell,
Survival,
Pathogen,
Â,
Private Securities Litigation Reform Act,
DOD,
Infection,
IPR,
Growth,
Severe acute respiratory syndrome coronavirus 2,
Therapy,
Disease,
Program,
CMC,
NSCLC,
Safety,
Heat Biologics,
Drug development,
Company,
Marketing,
Immune system,
FDA,
GLOBE,
Patient,
SEC,
Vaccine,
Anthrax,
Malaria,
Time,
The American,
Annual report,
Research,
Cancer,
Conference,
Quality control,
Nasdaq,
Sale,
NIH,
Association,
Terminology,
AACR,
D,
Investment,
Obiltoxaximab,
Form 10-K,
Acquisition,
Efficiency,
NYSE,
COVID-19,
Pharmaceutical industry,
Elusys Therapeutics,
Heat DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Heat) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the year ended December 31, 2021.
Key Points:
- DURHAM, N.C., March 14, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (Heat) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today provided strategic, financial, and operational updates for the year ended December 31, 2021.
- Jeff Wolf, Chief Executive Officer of Heat, commented, 2021 was a transformative year for Heat as we progress our strategic evolution to become a fully-integrated biopharmaceutical company.
- With the formation of Skunkworx Bio, we have ramped up our in-house discovery of biologics for our preclinical and clinical development efforts.
- Heat Biologics is a biopharmaceutical company focused on developing first-in-class therapies and vaccines to modulate the immune system.
